Deerfield Management Company, L.P. (Series C) Eye Point Pharmaceuticals, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $4.84 Billion
- Q1 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 579,594 shares of EYPT stock, worth $5.04 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
579,594Holding current value
$5.04 Million% of portfolio
0.25%Shares
1 transactions
Others Institutions Holding EYPT
# of Institutions
176Shares Held
53.9MCall Options Held
764KPut Options Held
1.57M-
Cormorant Asset Management, LP Boston, MA6.89MShares$60 Million8.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.76MShares$41.4 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.76MShares$32.7 Million3.33% of portfolio
-
Franklin Resources Inc San Mateo, CA3.39MShares$29.5 Million0.02% of portfolio
-
Black Rock Inc. New York, NY2.79MShares$24.3 Million0.0% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $296M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...